Specialty Pharmacy Continuum

Long-term data on vedolizumab in 5,008 patients with UC or Crohn's disease showed no significant difference in serious infections vs other biologics. Miguel Regueiro, MD, also reviews a VARSITY post hoc analysis. f.mtr.cool/zpvc9yq2f5 #IBD #UlcerativeColitis #CrohnsDisease #SpecialtyPharmacy

Could ChatGPT stand in for pharmacist judgment? In 48 simulated patient cases it evaluated 23 accurately but missed or flagged nonexistent medication problems in the other 25, underscoring the need for AI literacy in pharmacy education. Read more: f.mtr.cool/9hje4yw7b5 #PharmacyEducation #SpecialtyPharmacy #AI

Could low-dose tamoxifen ("Babytam") reduce breast cancer events in women with noninvasive breast neoplasia? A pooled analysis presented at ASCO 2026 found a benefit in ER-positive disease that differed by menopausal status. f.mtr.cool/nxofx7kuoc #BreastCancer #Oncology #ASCO26

IV workflow management systems are moving beyond inpatient pharmacies into ambulatory infusion, 503B facilities and home infusion. Pharmacists at M Health Fairview, UAB and Nuvance share lessons from their rollouts. f.mtr.cool/6dfgzo85or #SterileCompounding #HomeInfusion

Can pill bottle weight serve as a proxy for adherence? At #AXS26, HealthBeacon said it plans to launch a countertop device that lets pharmacists receive reports and reach out to patients. f.mtr.cool/asqo70h52u #SpecialtyPharmacy #MedicationAdherence

Neoadjuvant chemoimmunotherapy was associated with a 29% lower risk of death than adjuvant therapy in resectable stage II-III NSCLC in a retrospective analysis at ASCO 2026. Experts note randomized data are lacking. f.mtr.cool/w886slm81e #NSCLC #LungCancer #ASCO26

Bringing barcode medication administration into the OR takes more than retrofitting inpatient workflows. Presenters at ASHP Midyear 2025 point to workflow redesign, simulation and multidisciplinary buy-in. f.mtr.cool/25kiddck4f #BCMA #MedicationSafety

Could some tardive dyskinesia reflect an underlying brain vulnerability? An imaging study of 453 patients suggests so, but two psychiatric pharmacists question the methods and say the findings need replication. f.mtr.cool/f1cwfsd1dw #TardiveDyskinesia #Schizophrenia

Passing the chamber test isn't the same as surviving real-world shipping. Cold chain experts say gaps in gel pack conditioning, payload sizing and route testing help explain why temperature excursions persist in specialty pharmacy. f.mtr.cool/yn74whiafm #SpecialtyPharmacy #ColdChain

Could a monoclonal antibody help protect patients who can't mount an immune response to COVID-19? Two studies of pemivibart suggest it is safe and effective as pre-exposure prophylaxis in advanced HIV and hematologic malignancies. f.mtr.cool/gly06ju50t #COVID19 #SpecialtyPharmacy #HIV

Could IV compounding software do more than track training? Spaulding Rehabilitation Network pharmacists added 35 tracked activities and 30 competencies over five years, and an expert says centralized documentation makes surveyor tracers smoother. f.mtr.cool/ph885cz5kv #SterileCompounding #HealthSystemPharmacy

In a prospective real-world study of 36 patients with UC or Crohn's disease starting guselkumab, a substantial number reached sonographic response and transmural healing by week 12, sustained through week 26. Reported at ACG 2026. f.mtr.cool/sjfsnt3ywg #ACG2026 #IBD #Guselkumab

At one Inova hospital, PACU medication overrides fell from 100% to 1.9% three months after profiled, EHR-connected ADCs went live, and to 0.78% at 12 months. Presented at ASHP Midyear 2025. f.mtr.cool/ngudlk1qyf #MedicationSafety #PharmacyInformatics #PACU

Why is vigilant care crucial in Huntington's Disease? In part 8, Dr. Erin Furr-Stimming concludes her Pharmacy Practice News interview, discussing the disease's impact on patients and their loved ones. Watch now: f.mtr.cool/fp6dqg5h0l #HuntingtonsDisease #SpecialtyPharmacy

What's next for symptomatic treatment in Huntington's Disease? In part 7, Dr. Erin Furr-Stimming discusses next-generation approaches to managing the disease. Watch now: f.mtr.cool/watsemal4c #HuntingtonsDisease #SpecialtyPharmacy

Relying on EHR or claims data alone can miss cancer deaths. At AMCP Nexus 2026, Tempus AI presented a composite mortality measure with 86.6% sensitivity and 96.2% specificity versus the NDI. f.mtr.cool/oo15o98lld #AMCPNexus #Oncology #RealWorldEvidence

Rare disease innovation may be shifting beyond clinical trials. Real-world evidence from everyday patient care is becoming a key driver—and specialty pharmacists are right in the middle of it: specialtypharmacycontinuum.c… #RareDiseases #SpecialtyPharmacy

Menopause care is becoming a more common pharmacy benefit among employers and insurers. At AMCP Nexus 2026, an Aetna pharmacy director outlined updated ACOG guidance, newer VMS drugs and why individualized assessment matters. f.mtr.cool/dwdx2ibqmx #AMCPNexus #Menopause #ManagedCare

Federal MFN drug pricing models may place few formal requirements on health plans—but speakers at AMCP Nexus 2026 say they are already shaping plan operations and contracting. Specialty Pharmacy Continuum has the details. f.mtr.cool/h7t40mmsa0 #AMCPNexus #ManagedCare #GLP1

Seven pediatric hospitals and three major distributors shared weekly inventory data on seven injectable oncology drugs in an EDSA pilot. No shortages occurred during the six-month run. f.mtr.cool/dp6z7uf7s8 #DrugShortages #SupplyChain